Sort   by:  
 Page size 
GenomicsGene expression profiling upon treatment with NTX-301
Gene expression profiling upon treatment with NTX-301
PRJNA778722 | ENA
GenomicsGene expression profiling upon treatment with NTX-301 in MV4-11
Gene expression profiling upon treatment with NTX-301 in MV4-11
PRJNA777427 | ENA
TranscriptomicsGene expression profiling upon treatment with NTX-301
A novel hypomethylating agent NTX-301 is a promising therapeutic agent for AML patients. To examine its mechanisms of action, we produced gene expression data upon treatment with NTX-301 or decitabine (DAC) in AML cell lines.
ORGANISM(S): Homo sapiens 
2022-04-20 | GSE188392 | GEO
GenomicsDNA methylation profiling upon treatment with NTX-301 or decitabine in AML cells
DNA methylation profiling upon treatment with NTX-301 or decitabine in AML cells
PRJNA777433 | ENA
TranscriptomicsGene expression profiling upon treatment with NTX-301 in MV4-11
A novel hypomethylating agent NTX-301 is a promising therapeutic agent for AML patients. To examine its mechanisms of action, we produced gene expression data upon treatment with NTX-301 or decitabine (DAC) in MV4-11 cell line.
ORGANISM(S): Homo sapiens 
2022-04-20 | GSE187285 | GEO
Methylation profilingDNA methylation profiling upon treatment with NTX-301 or decitabine in AML cells
A novel hypomethylating agent NTX-301 is a promising therapeutic agent for AML patients. To examine its mechanisms of action, we produced methylome data upon treatment with NTX-301 or decitabine (DAC) in MV4-11 cell line.
ORGANISM(S): Homo sapiens 
2022-11-30 | GSE187291 | GEO
Methylation profilingThe novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML
Combinations of Hypomethylating agents (HMA) and BCL-2 inhibitor venetoclax (VEN) are frontline therapies for patients with acute myeloid leukemia (AML) with high response rates, but patients ultimately relapse, especially those with TP53 mutations. We investigated therapeutic efficacy and mechanism...
ORGANISM(S): Homo sapiens 
2026-06-29 | GSE315409 | GEO
UnknownPreclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.
Not available
S-EPMC10947827 | biostudies-literature
UnknownIntegrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301.
Not available
S-EPMC10046470 | biostudies-literature
UnknownDo patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Not available
S-EPMC5565721 | biostudies-literature
Sort   by:  
 Page size